Skip to main content

Agora
Sign in

House bill · H.R. 9418 (119th Congress)

Access to Innovative Treatments Act of 2026

U.S. House of Representatives

Latest action Jun 24, 2026

Sponsor: Nanette Diaz Barragán (U.S. Representative, CA-44, Democratic)

Follow

Following needs an Agora account. You will sign in first, then come back to this page.

From Congress.gov and official rosters. This record was last updated Aug 1, 2026. About our data

Summary

Access to Innovative Treatments Act of 2026 This bill requires the Centers for Medicare & Medicaid Services (CMS) to review adverse national coverage determinations of drugs under Medicare within 30 days of receiving a request to do so. Specifically, the CMS must review within 30 days any denials or limitations of coverage that are inconsistent with the drug's approval by the Food and Drug Administration (FDA). The bill's requirements do not apply if the CMS already conducted such a review within a two-year period. The bill also prohibits the CMS from applying prior coverage determinations that were made for drugs before they were approved by the FDA if such determinations are inconsistent with the drug's approval.

Summary from the Congressional Research Service. How we handle summaries

Where it stands

Assigned to a committee for review.

  1. Introduced
  2. In committee
  3. Up for a vote
  4. Passed one chamber
  5. Passed
  6. Enacted

Committee

House Committee on Energy and Commerce · U.S. House of Representatives

Also referred to House Committee on Ways and Means · U.S. House of Representatives.

Your position on this bill

Choose the position closest to yours. You'll sign in or create an account to save it.

Sign in or create an account to give your position

Cosponsors

1

Cosponsors listed on Congress.gov, shown A to Z.

  • Republican1

Shown in neutral colors by design; Agora is non-partisan.

Full history

  1. Jun 24, 2026

    Introduced

    Introduced in House

    U.S. House of Representatives

  2. Jun 24, 2026

    Introduced

    Introduced in U.S. House

    U.S. House

  3. Jun 24, 2026

    Referred to committee

    Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  4. Jun 24, 2026

    Referred to committee

    Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  5. Jun 24, 2026

    Referred to committee

    Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Read the record